Chengnan Huang, PhD, MS
Postdoctoral Scholar
Anesthesia
School of Medicine

Antibody engineering and multi-specific antibody (drug conjugate) development for cancer therapy

Education & Training

Show all (4) Hide

• PhD Biology Tsinghua University 06/2023
• MS Pharmaceutical biotechnology Wageningen University & Research 08/2017
• Glycoscience National Institute for Bioprocessing Research and Training 07/2017
• BS Biotechnology China Agricultural University 06/2014

Publications (6)

Top publication keywords:
Injections, SubcutaneousAntibodies, MonoclonalSuspensionsViscosityPowdersSolutionsElectrolytes

• Quantifying Protein Shape to Elucidate Its Influence on Solution Viscosity in High-Concentration Electrolyte Solutions.
  Molecular pharmaceutics 2024 Tian Z, Jiang X, Chen Z, Huang C, Qian F
• A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age-related macular degeneration.
  Bioengineering & translational medicine 2023 Huang C, Wang Y, Huang J, Liu H, Chen Z, Jiang Y, Chen Y, Qian F
• Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.
  Bioengineering & translational medicine 2023 Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C, Chen Y, Qian F
• Multivalent nanobodies with rationally optimized linker and valency for intravitreal VEGF neutralization
  Chemical Engineering Science 2023 Huang C, Huang J, Zhu S, Tang T, Chen Y, Qian F
• Spray-Dried Monoclonal Antibody Suspension for High-Concentration and Low-Viscosity Subcutaneous Injection.
  Molecular pharmaceutics 2022 Huang C, Chen L, Franzen L, Anderski J, Qian F
• Hypoxia Alters Epigenetic and N-Glycosylation Profiles of Ovarian and Breast Cancer Cell Lines in-vitro.
  Frontiers in oncology 2020 Greville G, Llop E, Huang C, Creagh-Flynn J, Pfister S, O'Flaherty R, Madden SF, Peracaula R, Rudd PM, McCann A, Saldova R